Cargando…
Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma
BACKGROUND: We evaluated candidate circulating serum cytokines, chemokines and growth factors in patients with locally/regionally advanced melanoma receiving neoadjuvant ipilimumab with toxicity and clinical outcome. METHODS: Patients were treated with ipilimumab (10 mg/kg IV every 3 weeks, 2 doses)...
Autores principales: | Tarhini, Ahmad A., Zahoor, Haris, Lin, Yan, Malhotra, Usha, Sander, Cindy, Butterfield, Lisa H., Kirkwood, John M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570556/ https://www.ncbi.nlm.nih.gov/pubmed/26380086 http://dx.doi.org/10.1186/s40425-015-0081-1 |
Ejemplares similares
-
Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving Neoadjuvant Ipilimumab
por: Tarhini, Ahmad A., et al.
Publicado: (2014) -
Phenotypic and functional testing of circulating regulatory T cells in advanced melanoma patients treated with neoadjuvant ipilimumab
por: Retseck, Janet, et al.
Publicado: (2016) -
Pro-Inflammatory Cytokines Predict Relapse-Free Survival after One Month of Interferon-α but Not Observation in Intermediate Risk Melanoma Patients
por: Tarhini, Ahmad A., et al.
Publicado: (2015) -
Allergic Rhinitis and Its Relationship with IL-10, IL-17, TGF-β, IFN-γ, IL 22, and IL-35
por: Bayrak Degirmenci, P., et al.
Publicado: (2018) -
NET Formation in Bullous Pemphigoid Patients With Relapse Is Modulated by IL-17 and IL-23 Interplay
por: Giusti, Delphine, et al.
Publicado: (2019)